A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Phase 4

Completed

• Conditions: Hepatitis B, Chronic
• Interventions: Drug: peginterferon alfa-2a [Pegasys]

• Registration Number: NCT01519921
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B. Patients will be stratified into group A (treatment naïve patients) or B (YMDD mutant patients). All patients will receive PEGASYS 180 micrograms subcutaneously once weekly for 48 weeks, followed by 24 weeks of treatment-free follow up.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Primary Completion: 2008-06
• Study Completion: 2008-06
• Study First Submitted: 2012-01-05
• Study First Submitted QC: 2012-01-24
• Study First Posted: 2012-01-27
• Results First Submitted: 2015-12-17
• Results First Submitted QC: 2015-12-17
• Results First Posted: 2016-01-25
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-22
• Last Update Posted: 2016-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Adult patients, 18-65 years of age
• HBsAg +ve for more than 6 months, HBeAg +ve, AntiHBs -ve
• Detectable hepatitis B virus (HBV) DNA (>100,000 copies/mL)

Read More

Exclusion Criteria

• Coinfection with hepatitis A, hepatitis C or human immunodeficiency virus (HIV)
• Evidence of decompensated liver disease
• A medical condition associated with chronic liver disease other than viral hepatitis

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PEG-IFN alfa-2a (Treatment naïve)	peginterferon alfa-2a [Pegasys]	Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
PEG-IFN alfa-2a (YMDD mutant)	peginterferon alfa-2a [Pegasys]	Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72	Week 72	Participants with loss of hepatitis B virus e antigen (HBeAg) at the EOF period (24 weeks after the end of treatment) were classified as responders.
Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72	Week 72	Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (EOF) period (24 weeks after the end of treatment) were classified as responders.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Loss of Hepatitis B Surface Antigen At Week 48 and Week 72	Week 48 and Week 72	A responder was a participant who were analysed with loss of Hepatitis B Surface Antigen (HBsAg) at EOT and EOF period.
Percentage of Participants With ALT Normalization At Week 48 and Week 72	Week 48 and Week 72	Participants with ALT less than the upper limit of normal (ULN) at end of treatment (EOT) and EOF period were responders.
Number of Participants With Any Adverse Events and Any Serious Adverse Events	Up to Week 72	An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Events (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Participants with any AEs and any SAEs have been presented.
Percentage of Participants With Hepatitis B Virus DNA Below the Limit of Detection At Week 48 and Week 72	Week 48 and Week 72	Participants with HBV-DNA below the limit of detection i.e. \<174 copies/mL at EOT and EOF period were responders.
Percentage of Participants With a Combined Response At Week 48 and Week 72	Week 48 and Week 72	A responder with Combined Response was a participant with HBV-DNA\<100,000 copies/mL, HBeAg seroconversion (i.e. loss of HBeAg and presence of anti-HBe) and ALT normalization at EOT and EOF period.
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion	Week 48 and Week 72	A responder was a participant with loss of HBeAg and presence of anti-HBe at EOT and EOF period.
Percentage of Participants With Hepatitis B Surface Antigen Seroconversion At Week 48 and Week 72	Week 48 and Week 72	A responder was a participant with loss of HBsAg and presence of anti-HBs at EOT and EOF period.